Agilent announces collaboration with incyte to develop advanced companion diagnostics in hematology and oncology

Santa clara, calif.--(business wire)--agilent technologies inc. (nyse: a) today announced an agreement with incyte that will bring together agilent's expertise and proven track record in the development of companion diagnostics (cdx) to support the development and commercialization of incyte's hematology and oncology portfolio. the value of the companion diagnostics market is predicted to expand to nearly us $14b by 2030,1 driven in part by the power of these tests to inform treatment decisions.
A Ratings Summary
A Quant Ranking